Ibrutinib Retreatment Yields High Responses in Chronic Lymphocytic Leukemia
Fixed-dose ibrutinib plus venetoclax produces limited second malignancies among patients with chronic lymphocytic leukemia, says Paolo Ghia, MD, PhD.
PFS With Ibrutinib Combo is ‘Promising’ in Chronic Lymphocytic Leukemia
Ibrutinib plus venetoclax appears to be effective across the overall chronic lymphocytic leukemia population in the CAPTIVATE study, although progression-free survival is shorter for those with TP53 mutations.
Paolo Ghia, MD, PhD, on the Chemo-Free, All-Oral Regimen of Ibrutinib Plus Venetoclax for First-Line CLL at ASCO 2021
Paolo Ghia, MD, PhD, discussed data from the CAPTIVATE trial of ibrutinib/venetoclax in the frontline setting for chronic lymphocytic leukemia.